Pulmonary vascular disease & thromboembolism
Global, regional, and national burden of pulmonary arterial hypertension and related heart failure from 1990 to 2021, with predictions to 2050: insights from the global burden of disease study 2021
Authors' conclusion
From 1990 to 2021, the global burden of PAH and PAH-HF increased, with significant gender disparities.
Study context
- Population
- Global population; Pulmonary arterial hypertension (PAH) and PAH-related HF, 1990–2021
- Outcome
- Incidence, prevalence, deaths and DALYs of PAH and PAH-HF
- Follow-up
- 1990 to 2021
Methodological detailsjoinpoint regression, Bayesian age-period-cohort analysis, decomposition analysis, projections to 2050
- Joinpoint regression
- Bayesian age-period-cohort analysis
- Decomposition analysis
- Projections to 2050
Main finding
As reported in the abstract
Global age-standardised rates of PAH · 2021
Age-standardized incidence rate (ASIR)
0.52 per 100 000 population
ASPR
2.28 per 100 000 population
ASMR
0.27 per 100 000 population
ASDR
8.24 per 100 000 population
Observational data: associations, not effects.
Further findings
PAH burden by sex
- Females showed higher burdens in nearly all outcomes
PAH burden by country · 2021
- Zambia and Switzerland had the highest ASIR and ASPR; Mongolia the highest ASMR and ASDR
PAH-HF · 1990 to 2021
- Most HF subtypes showed declines in ASPR
Decomposition analysis
- Increases in PAH incidence, prevalence and DALYs attributed primarily to population growth; aging primarily drove increases in deaths
Projections · to 2050
- Continued growth in ASIR but declines in other burden indicators after 2021
Original publication
Global, regional, and national burden of pulmonary arterial hypertension and related heart failure from 1990 to 2021, with predictions to 2050: insights from the global burden of disease study 2021. Eur Heart J Qual Care Clin Outcomes. Published 24 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →